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Abstract How tyrosine kinases of the Src family regulate
platelet-derived growth factor (PDGF)-induced DNA synthesis
remains elusive. Here we show that the E1A antigen of adeno-
virus 5 overrides the G1 block elicited by the kinase-inactive
mutant SrcK3. This was dependent upon the CR2 region of
E1A that upregulated cyclin E and cyclin A and inactivated
the pocket protein pRb. E1A rescue was independent of pRb.
Expression of SrcK3 in ¢broblasts prevented PDGF-induced
expression of cyclins E and A. This e¡ect was overcome by
E1A. Constitutive expression of cyclins E and A, but not D1,
restored mitogenesis that was inhibited by SrcK3. We conclude
that both cyclin E and cyclin A are likely targets of Src medi-
ating PDGF-induced DNA synthesis. 0 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The tyrosine kinases of the Src family are transiently acti-
vated by a number of growth factors and play important roles
in DNA synthesis [1]. Inhibition of their function in vivo,
either by microinjection of a neutralising antibody common
to Src, Fyn and Yes, by overexpression of kinase-inactive
form of the enzymes (SrcK3, FynK3), or by treatment of
cells with a speci¢c inhibitor, prevented induction of DNA
synthesis [2^5]. Little is known about the components of the
signalling cascade initiated by Src although speci¢c substrates
have been recently identi¢ed. These include the adapter Shc,
the transcription factor STAT3 and the tyrosine kinase Abl
[5^7]. Furthermore, several reports indicated that expression
of c-myc is an important downstream target of Src [1].
Growth factors turn on signalling cascades that induce cell
cycle progression through the restriction point at late G1,
where cells are committed to S phase entry. One critical event
is the phosphorylation and inactivation of the pocket protein
pRb by cyclin-dependent kinases (cdk). Cdks are regulated by
various mechanisms including binding of cyclins (D for cdk4/6
and E and A for cdk2) and association of small inhibitors.
pRb inactivation is, however, not su⁄cient for S phase entry
and additional events including those regulated by cdk2 are
also required [8]. The signalling molecules activated by plate-
let-derived growth factor (PDGF) and responsible for late G1
progression are not known. Interestingly, microinjection of
blocking antibody into cycling cells indicated that Src kinases
were required for at least 8^10 h of mitogen stimulation [2,3].
Recently, we [7] and others [9] have shown that some viral
antigens, which are known to perturb the cell cycle machinery,
bypass the need of Src kinases for mitogenesis. This included
the large T antigen of SV40 and the E1B protein of human
adenovirus. Furthermore, this approach uncovered the tu-
mour suppressor p53 as a critical target of Src. As a conse-
quence, Src kinases are no longer required for mitogenic sig-
nalling in cells with inactivated p53. This accounts for the lack
of requirement for Src kinases in src3/3, fyn3/3, yes3/3
embryonic ¢broblasts that were previously immortalised
with the SV40 large T antigen [10]. Here we report that the
E1A antigen of human adenovirus 5 can also bypass the re-
quirement of Src kinases for mitogenesis. In addition, the use
of viral proteins de¢cient in interacting with speci¢c cell cycle
regulators allowed the identi¢cation of cyclin E and cyclin A
as putative e¡ectors of Src during late G1.
2. Materials and methods
2.1. Antibodies and DNA constructs
Cst1 antibody was described previously [3] and a⁄nity-puri¢ed and
concentrated as in [3]. E1A monoclonal antibody was a gift of Dr
Galas (CRBM, Montpellier, France). Cyclin D1, D2, E and A anti-
bodies were from Santa Cruz and Sigma respectively and anti-FLAG
from Sigma. pSGT constructs expressing SrcK3 and Src-like adapter
protein (Slap) have been described in [3,11], pcDNA3 constructs ex-
pressing 12S and 13S isoforms of E1A were from Dr Sardet (IGM,
Montpellier, France), E1A mutants [12] from Dr Amati (ISREC,
Epalinges, Switzerland), p16ink4a, p27Kip1 and pPSM.7LP [13]
from Dr Blanchard (IGM, Montpellier, France), and human cyclin
D1, E1 and A from Drs Baldin (CNRS, Toulouse, France), Sardet
(IGM, Montpellier, France) and Superti-Furga (EMBL, Heidelberg,
Germany) respectively. Vector expressing SrcK3/Y527F was de-
scribed in [14] and was subcloned in pBabe.
2.2. Cell culture and microinjection
Rbþ=þ and Rb3=3 mouse embryo ¢broblast (MEF) cells were pro-
vided by Dr Blanchard (IGM, Montpellier, France). Cells were cul-
tured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented
with glutamine and antibiotics (penicillin and streptomycin) at 37‡C in
a humidi¢ed 5% CO2 atmosphere. Cells were microinjected as in [3].
The medium was replaced with DMEM containing 0.5% serum for at
least 30 h for NIH3T3 and Rbþ=þ MEF and 3 days in the absence of
serum for Rb3=3 MEFs. DNA plasmids were injected into the nucleus
4 h prior to PDGF (20 ng/ml) stimulation and further incubated or
not for 6, 14 and 18 h in the case of cyclin D1 expression, cyclin A
expression and DNA synthesis respectively, before ¢xation. DNA syn-
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thesis was scored by performing bromodeoxyuridine (BrdU) incorpo-
ration assays as described in [3].
2.3. Retroviral infection and biochemistry
Retroviral infection was performed as in [15] with some modi¢ca-
tions. 100-mm-diameter culture dishes of BOSC cells were transfected
overnight with the retroviral pBabe-puro plasmid expressing SrcK3/
Y527F. The next day, transfection medium was replaced with 5 ml of
fresh medium. Viral particles were then harvested 24, 48 and 72 h
later by ¢ltering supernatants of the cells, and stored at 320‡C until
used for infection. NIH3T3 cells seeded into 100-mm-diameter culture
dishes were then infected with two additions of 5 ml of virus-contain-
ing supernatant at a 12-h interval in the presence of 10 Wg/ml Poly-
brene (Sigma). Infected cells were selected 48 h after the beginning of
the infection with 7 Wg/ml puromycin and resistant clones were
pooled. Cells were next plated onto plastic 60-mm-diameter culture
dishes, starved in 0.5% serum for 40 h, then stimulated with 20 ng/ml
of PDGF BB 0^16 h as indicated and lysed into RIPA bu¡er as
described in [7]. Western blotting from the whole cell lysate was per-
formed as in [7].
2.4. Immuno£uorescence
Immuno£uorescence was performed as described in [3]. To analyse
DNA synthesis, cells were incubated for 10 min with 1.5 M HCl,
washed three times with phosphate-bu¡ered saline (PBS) and stained
with monoclonal (1:50) anti-BrdU antibody (Pharmingen). Cyclin D1,
A and E1A proteins were visualised by incubation with speci¢c anti-
bodies. Coverslips were ¢nally stained with rhodamine-conjugated
anti-mouse antibody (ICN), washed in PBS containing 10 WM
Hoechst 33258 (¢nal concentration 1 mg/ml; Sigma), rinsed in water,
inverted and mounted in Moviol (Hoechst) on glass slides. Slides were
viewed with an Axiophot £uorescence microscope.
The percentage of injected cells that incorporated BrdU and that
synthesised cyclin A, for each coverslip, was calculated by the follow-
ing formula: % of BrdU-positive cells = (number of BrdU-positive
injected cells/number of injected cells)U100, % of cyclin A-positive
cells = (number of cyclin A-positive injected cells/number of injected
cells)U100.
3. Results
3.1. E1A overcomes the G1 block induced by SrcK3
Quiescent NIH3T3 ¢broblasts seeded onto glass coverslips
were microinjected with a plasmid-encoding kinase-inactive
SrcK3 alone or together with a vector expressing the 12S
E1A antigen of human adenovirus 5. Cells were then stimu-
lated with PDGF for 18 h. DNA synthesis was visualised by
adding BrdU in the medium that incorporates into the nucleus
during the S phase of the cell cycle. An example of such an
experiment is shown in Fig. 1A and statistical analysis is sum-
marised in Fig. 1B: as previously reported, SrcK3 strongly
inhibited the mitogenic response induced by PDGF and inhi-
bition was relieved by E1A coexpression. Similar results were
obtained with the 13S E1A protein (not shown). This mito-
genic rescue was still growth factor-dependent, as in our con-
ditions E1A per se did not signi¢cantly induce DNA synthe-
sis. Similar results were obtained in primary cultures of MEFs
(see Fig. 2) indicating that this e¡ect was not speci¢c to the
cell line used. The functional interaction between Src and E1A
was reinforced by rescuing the PDGF receptor signalling in
cells expressing Slap, which speci¢cally inhibits the Src mito-
genic function [11,16] (Fig. 1B).
3.2. CR2 domain of E1A is required to bypass the
SrcK3 G1 block
The mechanism by which E1A bypassed the Src require-
ment was next investigated with the use of E1A mutants.
These mutants have been previously characterised in their in-
ability to interact with various cell cycle regulators [17]. These
included E1A 2RCG defective in binding the transcription
coactivators p300/CBP, E1A v26^35 defective in binding the
inhibitor p21CIP1/Waf1 of cdk2 plus the transcription coac-
tivator p400, E1A 124,135A mutated in the CR2 region, de-
fective in targeting pRb and upregulating cyclins E and A
Fig. 1. Microinjection of E1A in NIH3T3 cells overcomes the G1
block induced by SrcK3 and Slap. A: E1A overrides the SrcK3 G1
block. NIH3T3 cells seeded onto coverslips were microinjected with
SrcK3-encoding construct (50 ng/ml), in the presence or the absence
of E1A construct (50 ng/ml) as indicated, and stimulated or not
with PDGF. Cells were ¢xed and processed for immuno£uorescence
as described in Section 2. Left panels show immunostaining of mi-
croinjected cells expressing SrcK3 (Kcst1); right panels show immu-
nostaining of cells that have incorporated BrdU as indicated
(KBrdU) B: E1A overrides the inhibitory e¡ect induced by SrcK3
and Slap. Cells were injected with indicated constructs (50 ng/ml),
and stimulated or not with PDGF as indicated. Cells were processed
for immuno£uorescence as described in Section 2. The percentage of
injected cells that incorporated BrdU for each coverslip was calcu-
lated by the following formula: % of BrdU-positive cells = (number
of BrdU-positive injected cells/number of injected cells)U100. The
mean of several independent experiments and standard deviation are
shown.
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[12]. While the ¢rst two mutants showed some rescue e¡ect,
E1A 124,135A could not reverse the G1 block induced by
SrcK3 (Fig. 1B)
3.3. Inactivation of pRb is not su⁄cient to override the
SrcK- G1 block
We next tested whether E1A acts by inactivating pRb. The
rescue e¡ect was analysed in the presence of a constitutively
active form of pRb (pPSM.7LP) which cannot be inhibited by
phosphorylation and the cdk4/6 inhibitor p16ink4a which pre-
vents endogenous pRb inactivation [13]. As shown in Fig. 2A,
E1A overrode the G1 block induced by SrcK3 in MEF cells.
However, signalling rescue was still observed when coexpress-
ing p16ink4a or PSM.7LP. In contrast, E1A function was
abolished by constitutive expression of the cdk2 inhibitor
p27Kip1. Similar results were obtained in NIH3T3 (not
shown) indicating that this e¡ect was not speci¢c to our pri-
mary culture of MEFs. We concluded that the signalling res-
cue observed with E1A does not involve pRb downregulation
but rather the stimulation of cdk2 activity. This also suggests
that besides the pRb pathway, Src may regulate important cell
cycle events for S phase entry. Indeed, we observed that
PDGF mitogenic response still required the Src pathway in
cells that do not express pRb: inactivation of the Src signal-
ling cascade either by SrcK3 or Slap constructs, or by injec-
tion of the Src-neutralising antibody cst1, all inhibited mito-
genesis in Rb3=3cells (Fig. 2B).
3.4. Src kinases regulate cyclin E and cyclin A expression in
cells stimulated by PDGF
We next tested the possibility that E1A overrides the SrcK3
G1 block by inducing constitutive expression of cyclins. For
this purpose, we ¢rst investigated whether Src regulates cy-
clins expression. As shown in Fig. 3A, PDGF induced syn-
thesis of cyclin A, as assessed by immuno£uorescence, which
was not observed in SrcK3-microinjected cells. In contrast,
cyclin D1 was detected in both injected and non-injected cells,
showing speci¢city of inhibition. This also indicated that Src
kinases might not be mandatory for expression of all cyclins
such as cyclin D1. Statistical analysis of these experiments
indicated that cyclin A was detected in less than 5% of quies-
cent cells, whereas up to 40% of cells had synthesised cyclin A
after PDGF stimulation. This response was abrogated by
SrcK3 (2%) but rescued by E1A coinjection (45%). The e¡ect
of SrcK3 on cyclin E level could not be investigated by this
approach due to the absence of appropriate reagent.
The incidence of Src kinases on cyclins was next analysed
biochemically. The kinase-inactive SrcK3/Y527F was ex-
pressed in NIH3T3 cells using a retroviral infection approach
[15]. This allows a high e⁄ciency (90^100%) of ectopic protein
expression with a ¢ve-fold overexpression relative to endoge-
nous Src kinases (as assessed by Western blotting with the
cst1 antibody that recognises Src, Fyn and Yes). Infected cells
were then made quiescent by withdrawing serum from the
medium, and further stimulated with PDGF for various
time periods. As shown in Fig. 3B, PDGF induced a strong
increase in cyclin A and cyclin E levels in mock-infected cells.
In cells expressing SrcK3/Y527F, both responses were largely
reduced (60 and 80% respectively) con¢rming our immuno-
£uorescence analysis. Cyclin D1 and D2 levels were also in-
creased during PDGF stimulation in control cells. While the
cyclin D2 response was attenuated to some extent by SrcK3/
Y527F, no signi¢cant inhibition of cyclin D1 expression was
observed.
3.5. Cyclin E and cyclin A override the SrcK3 G1 block
Finally, the functional consequence of cyclin inhibition was
analysed by performing microinjection rescue experiments. As
shown in Fig. 4, constitutive expression of cyclin A largely
restored PDGF receptor signalling in cells injected with
SrcK3. Observed DNA synthesis was dependent on the pres-
ence of growth factors as none of the cyclins induced any
response per se. A similar e¡ect was obtained with cyclin E.
Rescues were speci¢c to this type of cyclins as it was not
observed with cyclin D1. We conclude that both cyclin E
Fig. 2. Inactivation of pRb is not su⁄cient to override the require-
ment of Src kinases for mitogenesis. A: Inactivation of pRb is not
su⁄cient to override the G1 block induced by SrcK3. Rbþ=þ MEFs
seeded onto coverslips were microinjected with SrcK3 (50 ng/ml) in
the presence or not of E1A (50 ng/ml) constructs plus indicated
constructs (100 ng/ml) and stimulated or not with PDGF. B. Src ki-
nases are still required for PDGF mitogenesis in pRb-de¢cient cells.
Rb3=3 MEFs seeded onto coverslips were microinjected with
SrcK3- or Slap-encoding constructs (left panel), non-immune (IgG)
or cst1-neutralising antibody (right panel) as indicated and stimu-
lated or not with PDGF. Cells were ¢xed and processed for immu-
no£uorescence as described in Section 2. The percentage of injected
cells that incorporated BrdU for each coverslip was scored as in
Fig. 1. The mean of several independent experiments and standard
deviation are shown.
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and cyclin A are putative downstream e¡ectors of the Src
pathway during PDGF receptor signalling.
4. Discussion
Here we show that adenovirus antigen E1A bypasses the
requirement of Src kinases for growth factor receptor signal-
ling in ¢broblasts. In addition our data show that cyclins E
and A are likely targets of the Src pathway in late G1. This
notion is in agreement with previous reports indicating that
Src regulates induction of cyclin A by cell adhesion [18] or by
expression of the viral protein HBx [19], or that cyclins E and
A are upregulated during vSrc-induced cell transformation
[20]. Src-induced cyclin A expression may involve pRb phos-
phorylation [21,22], as suggested by the partial requirement of
Src for cyclin D expression. Additionally, Src may use an
alternative mechanism that is independent of pRb and that
implicates cyclin E [13,23]. How Src mediates cyclin E expres-
sion is not known. However, Myc has been involved in the
expression of cyclin E [24] and several reports including ours
Fig. 3. Src kinases regulate PDGF-induced cyclin E and A expression. A: NIH3T3 cells seeded onto coverslips were microinjected with SrcK3-
encoding constructs, in the presence or the absence E1A as indicated, and stimulated or not with PDGF. Cells were ¢xed and processed for im-
muno£uorescence as described in Section 2. Left panel shows microinjected cells expressing SrcK3, right panel shows immunostaining of cyclin
D1 or cyclin A as shown. B: NIH3T3 cells infected with wild type retroviruses (mock) or retroviruses expressing SrcK3/Y527F as indicated
were made quiescent and stimulated for the indicated hours with PDGF. Cell lysates were made as described in Section 2 and the level of Src
kinases (Src, Fyn and Yes) and the cyclins D1, D2, E and A was assessed by Western blotting using speci¢c antibody as indicated in Section 2.
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have shown that Myc is an important target of the Src path-
way [5,7,25]. Therefore one mechanism would be that Src ki-
nases induce cyclin expression through Myc.
Finally our data strongly suggest that Src and Ras lie in
separate pathways for PDGF-induced cell cycle progression at
late G1. pRb is the main target of Ras as it is no longer
required for mitogenesis in Rb3=3 cells [26]. In contrast our
data clearly show that Src also regulates cell cycle regulatory
proteins independent of pRb, which are important for DNA
synthesis and targeted by E1A. The best illustration is the
requirement of Src for mitogenesis observed in pRb-de¢cient
cells. In line with this, we also observed that ectopic expres-
sion of cyclin D1 does not overcome the G1 block induced by
SrcK3 (Fig. 4) while it does when induced by RasN17 (not
shown). One of these important Src targets probably includes
cyclin E. This notion is supported by the capacity of ectopic
cyclin E to rescue mitogenesis that was inhibited by SrcK3.
However, the fact that the E1A rescue e¡ect was blocked by
the cdk2 inhibitor p27Kip1 suggests that Src may target addi-
tional regulators of cdk2. The identi¢cation of such regulators
that drive cells in late G1 needs further investigation.
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Fig. 4. Constitutive expression of cyclin A or cyclin E overrides the
G1 block elicited by SrcK3. NIH3T3 cells (A) or primary culture
of MEFs (B) seeded onto coverslips were microinjected with SrcK3-
encoding construct (50 ng/ml), in the presence or the absence of
constructs expressing cyclin A, E or D1 as indicated (100 ng/ml),
and stimulated or not with PDGF. Cells were ¢xed and processed
for immuno£uorescence as described in Section 2. The percentage of
injected cells that incorporated BrdU for each coverslip was scored
as in Fig. 1. The mean of several independent experiments and stan-
dard deviation are shown.
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